# Bioequivalence Study of Flibanserin From AphroFemine 100 mg F.C.T (Bio Med for Pharmaceuticals Industries (BIOMED), Egypt) Versus Addyi 100 mg Tablets (Sprout Pharmaceuticals, Inc., USA)

> **NCT04494191** · PHASE1 · COMPLETED · sponsor: **Genuine Research Center, Egypt** · enrollment: 26 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Flibanserin 100Mg Tab
- **DRUG:** Flibanserin 100 MG [Addyi]

## Key facts

- **NCT ID:** NCT04494191
- **Lead sponsor:** Genuine Research Center, Egypt
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-12
- **Primary completion:** 2018-12-19
- **Final completion:** 2019-02-27
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2020-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04494191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04494191, "Bioequivalence Study of Flibanserin From AphroFemine 100 mg F.C.T (Bio Med for Pharmaceuticals Industries (BIOMED), Egypt) Versus Addyi 100 mg Tablets (Sprout Pharmaceuticals, Inc., USA)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04494191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*